Adaptive Biotechnologies Corp Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Adaptive Biotechnologies Corp quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2018 to Q3 2024.
  • Adaptive Biotechnologies Corp Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $13.5M, a 11.8% decline year-over-year.
  • Adaptive Biotechnologies Corp Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $56.3M, a 8.62% decline year-over-year.
  • Adaptive Biotechnologies Corp annual Share-based Payment Arrangement, Expense for 2023 was $62.9M, a 13.4% increase from 2022.
  • Adaptive Biotechnologies Corp annual Share-based Payment Arrangement, Expense for 2022 was $55.5M, a 28.3% increase from 2021.
  • Adaptive Biotechnologies Corp annual Share-based Payment Arrangement, Expense for 2021 was $43.3M, a 74.7% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $56.3M $13.5M -$1.81M -11.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $58.1M $13M -$4.39M -25.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $62.5M $14.3M -$373K -2.54% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $62.9M $15.6M +$1.26M +8.83% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $61.6M $15.3M +$1.19M +8.44% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $60.5M $17.3M +$3.17M +22.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $57.3M $14.7M +$1.81M +14.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $55.5M $14.3M +$2.42M +20.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $53.1M $14.1M +$2.5M +21.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $50.6M $14.2M +$2.93M +26.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $47.6M $12.9M +$4.38M +51.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $43.3M $11.9M +$4.63M +64% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $38.6M $11.6M +$5.17M +80% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $33.4M $11.2M +$4.88M +76.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $28.6M $8.48M +$3.81M +81.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $24.8M $7.24M +$3.83M +112% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-14
Q3 2020 $20.9M $6.47M +$3.14M +94% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $17.8M $6.37M +$3.04M +91.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $14.8M $4.68M +$1.63M +53.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $13.1M $3.41M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 $3.34M +$782K +30.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $3.33M +$884K +36.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $3.05M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q3 2018 $2.55M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $2.45M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.